Literature DB >> 2391741

Inappropriate use of oral ciprofloxacin.

T R Frieden1, R J Mangi.   

Abstract

More than $2.4 billion is spent annually on oral antibiotics. Their inappropriate use is common, and newer ones offer expanded and expensive opportunities for abuse. Ciprofloxacin, an oral quinolone with systemic absorption and broad antimicrobial spectrum, illustrates this pattern. Since its release in the US in October 1987, ciprofloxacin has rapidly become one of the most frequently prescribed oral antibiotics. We have observed widespread inappropriate use of ciprofloxacin and describe several patterns of misuse. The activity of ciprofloxacin against streptococci, anaerobic organisms, and Mycoplasma ranges from intermediate to poor. Properly used, ciprofloxacin can extend the range of oral therapy. However, ciprofloxacin is inappropriate initial therapy for common outpatient infections, including otitis media, sinusitis, pharyngitis, and pneumonia.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2391741

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  22 in total

Review 1.  The next generation: fluoroquinolones in the management of acute lower respiratory infection in adults.

Authors:  P J Moss; R G Finch
Journal:  Thorax       Date:  2000-01       Impact factor: 9.139

2.  Selling drugs to the public--should the UK follow the example of the US?

Authors:  John Frey
Journal:  Br J Gen Pract       Date:  2002-02       Impact factor: 5.386

3.  Selling drugs to doctors--it's marketing, not education.

Authors:  Richelle Cooper; Jerome Hoffman
Journal:  Br J Gen Pract       Date:  2002-02       Impact factor: 5.386

4.  Fluoroquinolone Resistance in Salmonella and the Utility of Pefloxacin Disk Diffusion [corrected].

Authors:  Ferric C Fang
Journal:  J Clin Microbiol       Date:  2015-08-26       Impact factor: 5.948

Review 5.  Optimum treatment of streptococcal pharyngitis.

Authors:  F Scaglione; G Demartini; M M Arcidiacono; J P Pintucci
Journal:  Drugs       Date:  1997-01       Impact factor: 9.546

6.  Drug prices and third party payment: do they influence medication selection?

Authors:  J E Hux; C D Naylor
Journal:  Pharmacoeconomics       Date:  1994-04       Impact factor: 4.981

Review 7.  Oral ciprofloxacin: a pharmacoeconomic evaluation of its use in the treatment of serious infections.

Authors:  J A Balfour; D Faulds
Journal:  Pharmacoeconomics       Date:  1993-05       Impact factor: 4.981

8.  Risk of pneumococcal septicaemia in patients with chronic lymphoproliferative malignancies.

Authors:  R Gowda; F M Razvi; G P Summerfield
Journal:  BMJ       Date:  1995-07-01

Review 9.  The value of new antimicrobial agents.

Authors:  J H Wagenvoort
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1993       Impact factor: 3.267

10.  Ciprofloxacin-induced, low-level resistance to structurally unrelated antibiotics in Pseudomonas aeruginosa and methicillin-resistant Staphylococcus aureus.

Authors:  J Fung-Tomc; B Kolek; D P Bonner
Journal:  Antimicrob Agents Chemother       Date:  1993-06       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.